Citation
González-Chávez, Zabdi, et al. "Gamma-glutamylcysteine Synthetase and Tryparedoxin 1 Exert High Control On the Antioxidant System in Trypanosoma Cruzi Contributing to Drug Resistance and Infectivity." Redox Biology, vol. 26, 2019, p. 101231.
González-Chávez Z, Vázquez C, Mejia-Tlachi M, et al. Gamma-glutamylcysteine synthetase and tryparedoxin 1 exert high control on the antioxidant system in Trypanosoma cruzi contributing to drug resistance and infectivity. Redox Biol. 2019;26:101231.
González-Chávez, Z., Vázquez, C., Mejia-Tlachi, M., Márquez-Dueñas, C., Manning-Cela, R., Encalada, R., Rodríguez-Enríquez, S., Michels, P. A. M., Moreno-Sánchez, R., & Saavedra, E. (2019). Gamma-glutamylcysteine synthetase and tryparedoxin 1 exert high control on the antioxidant system in Trypanosoma cruzi contributing to drug resistance and infectivity. Redox Biology, 26, 101231. https://doi.org/10.1016/j.redox.2019.101231
González-Chávez Z, et al. Gamma-glutamylcysteine Synthetase and Tryparedoxin 1 Exert High Control On the Antioxidant System in Trypanosoma Cruzi Contributing to Drug Resistance and Infectivity. Redox Biol. 2019;26:101231. PubMed PMID: 31203195.
TY - JOUR
T1 - Gamma-glutamylcysteine synthetase and tryparedoxin 1 exert high control on the antioxidant system in Trypanosoma cruzi contributing to drug resistance and infectivity.
AU - González-Chávez,Zabdi,
AU - Vázquez,Citlali,
AU - Mejia-Tlachi,Marlen,
AU - Márquez-Dueñas,Claudia,
AU - Manning-Cela,Rebeca,
AU - Encalada,Rusely,
AU - Rodríguez-Enríquez,Sara,
AU - Michels,Paul A M,
AU - Moreno-Sánchez,Rafael,
AU - Saavedra,Emma,
Y1 - 2019/05/28/
PY - 2018/12/10/received
PY - 2019/01/31/revised
PY - 2019/05/27/accepted
PY - 2019/6/17/pubmed
PY - 2020/2/29/medline
PY - 2019/6/17/entrez
KW - Benznidazol
KW - Flux control coefficient
KW - Gamma-glutamylcysteine synthetase
KW - Trypanothione
KW - Trypanothione reductase
KW - Trypanothione synthetase
KW - Tryparedoxin
SP - 101231
EP - 101231
JF - Redox biology
JO - Redox Biol
VL - 26
N2 - Trypanothione (T(SH)2) is the main antioxidant metabolite for peroxide reduction in Trypanosoma cruzi; therefore, its metabolism has attracted attention for therapeutic intervention against Chagas disease. To validate drug targets within the T(SH)2 metabolism, the strategies and methods of Metabolic Control Analysis and kinetic modeling of the metabolic pathway were used here, to identify the steps that mainly control the pathway fluxes and which could be appropriate sites for therapeutic intervention. For that purpose, gamma-glutamylcysteine synthetase (γECS), trypanothione synthetase (TryS), trypanothione reductase (TryR) and the tryparedoxin cytosolic isoform 1 (TXN1) were separately overexpressed to different levels in T. cruzi epimastigotes and their degrees of control on the pathway flux as well as their effect on drug resistance and infectivity determined. Both experimental in vivo as well as in silico analyses indicated that γECS and TryS control T(SH)2 synthesis by 60-74% and 15-31%, respectively. γECS overexpression prompted up to a 3.5-fold increase in T(SH)2 concentration, whereas TryS overexpression did not render an increase in T(SH)2 levels as a consequence of high T(SH)2 degradation. The peroxide reduction flux was controlled for 64-73% by TXN1, 17-20% by TXNPx and 11-16% by TryR. TXN1 and TryR overexpression increased H2O2 resistance, whereas TXN1 overexpression increased resistance to the benznidazole plus buthionine sulfoximine combination. γECS overexpression led to an increase in infectivity capacity whereas that of TXN increased trypomastigote bursting. The present data suggested that inhibition of high controlling enzymes such as γECS and TXN1 in the T(SH)2 antioxidant pathway may compromise the parasite's viability and infectivity.
SN - 2213-2317
UR - https://www.unboundmedicine.com/medline/citation/31203195/Gamma_glutamylcysteine_synthetase_and_tryparedoxin_1_exert_high_control_on_the_antioxidant_system_in_Trypanosoma_cruzi_contributing_to_drug_resistance_and_infectivity_
L2 - https://linkinghub.elsevier.com/retrieve/pii/S2213-2317(18)31207-2
DB - PRIME
DP - Unbound Medicine
ER -